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Abstract 
The growing use and investigation of pharmaceuticals to treat disease has 
offered the field of drug delivery an opportunity to further improve upon the 
effects provided, as well as address therapeutic complications. An effective long-
term treatment for rheumatoid arthritis (RA) has yet be developed, while many 
current treatments pose disadvantageous side effects due to undesirable reactions 
outside of the diseased tissue.  Therefore, there is a need for an improved strategy 
for RA treatment.  A previously developed drug carrier system based on 
polysialic acid (PSA) and polycaprolactone (PCL) micelles was shown to be 
effective for in vitro therapeutic use.  The evaluated PSA-PCL micelles were 
capable of passively accumulating in joint tissue.  To actively target diseased 
tissue, the possibility of improving site specificity through the addition of 
hyaluronic acid (HA) was explored further here.  These micelles were synthesized 
from separate PSA and PCL polymer conjugates, incorporating HA to the micelle 
backbone. However, initial characterization revealed large, inconsistent, and 
unstable micelle structures poorly suited for effective drug delivery.  Therefore, 
additional research is warranted to identify and develop targeted, polysaccharide-
based micelles.
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Synthesis and Evaluation of Polysialic Acid-Polycaprolactone Based Micelles 
for Drug Delivery 
 
Executive Summary 
 
 
 The pharmaceutical industry is a vast and capitalizing field, with research 
institutions and universities across the world funneling large amounts of resources 
into pharmaceutical research.  Almost $800 billion is spent on pharmaceutical 
research and sales within the U.S. annually.  The drug development procedure 
usually spans 10-15 years from the start of initial research through clinical trials, 
and can require $1-2 billion of initial investment in that time.  Therefore, any 
potential to improve a drug’s effectiveness and reduce unfavorable side effects is 
of medical and economic interest.  Controlled pharmaceutical transportation 
within the body by drug delivery systems can be used to accomplish such 
objectives.  This project aims to evaluate a method to increase drug efficacy while 
reducing side effects by exploring the viability of adding a tissue-specific 
targeting element on an existing drug delivery platform.     
Rheumatoid arthritis (RA) is the primary focus of this project, with 
possible applications to other inflammatory diseases.  Although a number of FDA 
drugs exist for RA management, there lacks a long-term treatment that 
consistently and effectively alleviates inflammatory symptoms from patient to 
patient and has minimal side effects.  Tofacitinib (commonly known as Xeljanz) 
is of key interest in this project due to its past clinical success, although many 
users still experience adverse events.  The circulation of the drug throughout the 
body post-injection has adverse effects as the drug reacts in unintended areas.  
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Altering inflammatory and immune responses outside of the diseased site can put 
the patient at risk of chronic infection.  Integrating a site-specific carrier system 
with current RA treatments in order to preferentially localize small molecule 
therapeutics to diseased tissue will increase drug efficacy while avoiding the 
complications that arise with non-site specific drug delivery.   
 Throughout the body, different cells and tissues possess differing 
attributes that can allow their individual distinction.  Specifically, RA synovial 
fibroblasts (RASFs) are found locally around joint tissue and have a specific 
receptor for hyaluronic acid (HA).  HA is a glycosaminoglycan (GAG), which is a 
long unbranched polysaccharide consisting of repeating disaccharide monomers. 
The external receptors on the RASFs allow for potential drug localization through 
active targeting of an encapsulated drug to these sites by preferentially binding 
attached HA molecules. 
 The active targeting of a small molecule drug like tofacitinib involves the 
use of a carrier system for drug delivery.  In this work, the proposed carrier 
system is a polymer micelle, or self-assembling particle, that can be loaded with a 
drug and linked with HA.  This project focused on the addition of an active 
targeting element onto an existing micelle system.  The new system proposes a 
mechanism that results in greater site specificity, as well as increased circulation 
time and decreased degradation by shielding the encapsulated drug.  Polysialic 
acid (PSA) is a hydrophilic saccharide polymer that has ben previously shown to 
work well as part of a carrier system.  Micelles form spherical particles as a result 
of having a hydrophilic (water-loving) region, and hydrophobic (water-resistant) 
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region.  When in an aqueous environment, the hydrophobic constituents gather as 
far away from the aqueous surroundings, while the hydrophilic segments 
assemble to face the outside, thus forming an enclosed sphere.  The PSA 
functions as the hydrophilic element, while polycaprolactone (PCL), a polyester 
with long carbon chains, acts as the hydrophobic component.  Linking a PSA-
PCL copolymer with HA is anticipated to result in the ability to preferentially 
deliver the micelle to RASF receptors. 
To synthesize the micelles, PSA and PCL were linked through functional 
groups along the polymer backbone before HA was similarly added to the 
polymer chain.  The conjugation was performed at a specified percentage of PCL 
and HA allowing only a small number of sialic acid monomers to be reacted, 
leaving room for micelle assembly and further additions.  The constrained 
equivalents also facilitated control over the micelle size and physical 
characteristics.  The critical micelle concentration (CMC) is a measure of the 
density at which the polymers arrange into micelles.  This was determined by 
fluorescence testing, using pyrene as a marker for when micelles formed.  As 
micelles form, they encapsulate the small pyrene molecule, which alters its 
environment into the hydrophobic inside of the micelle, and shifts the pyrene 
fluorescent output.  When a range of concentrations are used, the shift can be 
seen, yielding the critical micelle concentration as the inflection point of the 
curve.  Additional metrics used to characterize micelles are size and zeta 
potential.  The size of the micelle effects how the body perceives it.  Renal 
clearance and immunologic systems constantly act to remove the micelle and 
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encapsulated drug from the body.  An optimal size is around 20-200nm, being 
large enough to avoid small ion filtration, yet small enough to not provoke an 
immune response.  The zeta potential is a measure of the charged 
attraction/repulsion forces within the micelle solution.  In order for stable micelle 
formation, micelles should possess a zeta potential between an absolute value of 
30 and 40 mV. 
After completing polymer synthesis, we found the PSA-PCL conjugate 
polymer showed a low CMC (37 μg/mL) as well as relatively small micelle size 
(≤50nm), consistent with previous tests on PSA-PCL.  The PSA-PCL-HA was 
similarly characterized, having a critical micelle concentration of around 169 
μg/mL and a dispersed size distribution ≥100nm.  This increase in CMC and size 
can be attributed to the HA addition, sterically hindering micelle formation 
through the size of the molecule.  The variable size associated with PSA-PCL-HA 
suggests inconsistent micelle formation and a lack of reproducibility, traits not 
conducive to drug delivery.  The greatest concern with a larger CMC values is the 
possibility of dissociation in the body.  It is known that when administered to a 
patient, the micelle-encapsulated therapeutic is readily diluted throughout the 
body’s fluid volume, potentially causing micelle collapse if the CMC is not 
reached.  To address this issue, the PSA-PCL-HA was remade with only half of 
the initial HA amount.  The resulting compound was characterized as before, with 
very little change in CMC and size measurements.  It was therefore concluded 
that using a single polymer system to incorporate HA did not show potential as a 
targeted drug delivery system.   
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In an attempt to address the resulting problems with PSA-PCL-HA 
conjugation, a novel approach was explored in which separate blocked polymers 
were made with PSA-PCL and PCL-HA, co-assembled to micelles.  The 
separated HA and PSA components were anticipated to form an aggregate micelle 
with randomly dispersed PSA-PCL and HA containing regions.  The reduced 
block polymer size would hopefully correlate to a reduced micelle size.  In a 
similar reaction to conjugating PCL to PSA, the backbone carbonyl groups of the 
HA polymer were used to attach PCL, resulting in an amphipathic (containing 
both hydrophilic and hydrophobic regions) molecule.  A 5wt% combination of 
PSA-PCL and PCL-HA was made in order to maintain the previous ratio of HA 
within the micelle structure, and subjected to CMC and size testing.  Even greater 
size distributions were seen with this approach, with possible segregation between 
the PSA and HA containing polymers.   
Each explored method of HA incorporation within the established PSA-
PCL micelles revealed material properties that are not well suited for a functional 
drug delivery system.  Micelle formation was characterized by increased CMC 
values and highly dispersed size.  The inconsistent nature of the synthesized 
polymer micelles posed problems with reproducible results and viability as a 
therapeutic tool.  Although the developed micelle systems were not ideal for drug 
delivery, the success of previous PSA-PCL micelles warrants further research to 
identify possible solutions to create targeted polysaccharide-based drug carrier 
systems. 
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Advice to Future Honors Students 
To my fellow honors students:  As an engineer, I have had the opportunity 
to be a part of multiple amazing research opportunities.  Each has been unique 
and, dare I say, exceptionally educational.  In a scientific or engineering major, 
early experience is very valuable and motivational as you can apply what you 
have learned in the classroom.  Many struggle to initially get research experience 
on campus, despite its importance.  The advice I would give you is to be proactive 
in your search for experience.  Go to office hours of professors the first week of 
class your first semester at school.  Get to know them, and for them to know you.  
Show interest in what they do.  Now, when you ask to work in their lab, they 
know you and your character.  Getting that first project cannot come soon enough, 
as that leads to another project, and another, and then with your capstone, you 
have a full, competitive résumé; this leads to internships (money!) and job offers 
(lots of money!) or graduate school admissions.  Whatever your aspirations, be 
proactive and go get it.     
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Chapter 1 
Introduction to Drug Delivery & Rheumatoid Arthritis 
 
 
 
 
 
 When addressing ailments of the human body, there has been an increased 
utilization of directed small molecule pharmaceuticals to target biological 
pathways and elements.1,2  The drug development procedure usually spans 10-15 
years from the start of initial research through clinical trials, and can require $1-2 
billion of primary capital investment over that time.3 Therefore, any potential to 
improve a drug’s effectiveness and reduce unfavorable side effects is of medical 
and economic interest.  The focus of modern drug design is primarily to identify 
and target specific abnormality related to the cause of a disease.  These 
irregularities can take many shapes, and require large time commitments to fully 
understand due to the highly complex mechanisms and signaling pathways they 
can affect.  For example, multiple types of nonmelanoma skin cancers like 
squamous cell carcinoma overexpress regulatory proteins involved in cell cycle 
progression.  Therefore, a logical treatment path would be to discern the involved 
proteins and the specific affects of their overexpression.  Then, an exclusive small 
molecule inhibitor could be designed to down regulate that protein, hopefully 
restoring homeostatic conditions. 
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 With the in vivo delivery of small molecule drugs, side effects commonly 
arise attributed to the non-site specific nature of the treatment.  An intravenously 
delivered drug circulating in the bloodstream will interact with healthy tissue, 
even with a preferential passive pathway such as increased vasculature leakage or 
cell division in particular tissues related to certain diseases.  A well-known 
example is the severe nausea and hair loss associated with chemotherapy.  Toxic 
chemotherapeutic drugs have an increased effect on cells with high proliferation 
rates, most characteristic of the invasive tumorous tissue, however, the fast 
dividing stomach lining and hair follicle cells are equally effected.4  Alternate 
approaches are being explored to potentially alleviate adverse side effects by 
using a drug delivery carrier system to 1) increase circulation time in the body for 
passive targeting, 2) prevent therapeutic degradation, and 3) improve treatment 
site specificity, reducing any related unfavorable effects.   
 Rheumatoid arthritis (RA) is a chronic autoimmune disease associated 
with progressive debility and additional medical complications.  RA is 
characterized by chronic inflammation and swelling, with articular joint 
localization, ultimately leading to joint pain and destruction.  Consequently, 
cartilage, bone, and RA synovial fibroblasts (RASFs) are predominately affected 
and involved in the mechanisms behind RA origination and development, with 
chemical linkages to immune cells like B and T cells.  Disparities in signaling 
anti-inflammatory and pro-inflammatory cytokines released by articular cells like 
RASFs have been particularly well linked to the inflammation and tissue 
degradation associated with RA.5-6  They play a central role in the signaling from 
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local macrophage cells, osteoclasts (and other degradative cells), and immune 
system elements.  Most commonly, signaling molecules such as tissue necrosis 
factor α (TNF-α) and the interleukin (IL) family (most notably IL-6, IL-8 and IL-
1β) are involved as pro-inflammatory immune system promoters, directing 
leukocytes/ lymphocytes to the joint.5,7,8   
 Additional pathways have also been explored as possible therapeutic 
targets, involving janus kinase/ signal transducer and activator of transcription 
(JAK/STAT) signaling.  These kinases, JAK1, JAK2, JAK3, act through specific 
tyrosine residue phosphorylation.  Upon phospho-activation, JAK molecules 
conjugate with and phosphorylate localized STATs, initiating their dimerization 
and nuclear relocation, where they act as pro-inflammatory transcription 
factors.9,10  Consequently, the development of JAK inhibitor drugs has provided a 
possible treatment path that utilizes a differing approach to traditional 
therapeutics.  One such example is tofacitinib, a JAK inhibitor (JAK1 and JAK3 
preferentially) that has shown clinical success and gained FDA approval, although 
still exhibits adverse side effects in some patients. The positive anti-inflammatory 
properties of this drug suggests that through localization and controlled 
administration, the side effects could be greatly reduced while improving drug 
efficacy.   
A modified polysialic acid (PSA)-polycaprolactone (PCL) based drug 
carrier system is hypothesized to achieve these enhancements.  PSA-PCL micelle 
systems have previously shown success with drug delivery, allowing prolonged 
circulation times and thus passive accumulation in diseased tissue.  The proposed 
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addition of a targeting element aims to increase site specificity, while benefiting 
from advantages of the micelle system.  Incorporating a targeting element to the 
micelle requires a distinguishing element.  In this case, the RASFs contain CD44 
receptors that bind hyaluronic acid (HA).  By synthesizing a micelle with 
conjugated HA at the surface, the micelle could be preferentially targeted to these 
cells in the tissue of interest.  Therefore, both active and passive targeting could 
be used to specify drug accumulation at the site of interest. 
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Chapter 2 
PSA-PCL-HA Polymers: Synthesis Methods 
 
 
 
 
 
 Polysialic acid (PSA) has shown to be an effective hydrophilic foundation 
for carrier systems, extending circulation times and preventing therapeutic 
degradation, ultimately improving drug efficacy.11-14  The amphipathic 
characteristics for micelle formation are satisfied when linked with the 
hydrophobic polyester polycaprolactone (PCL).  Previously in the Bader lab, this 
PSA-PCL conjugate has been demonstrated to effectively load and deliver small 
molecule drugs in vitro.14  Here, additional conjugation methods of a 
chondrocyte-targeting hyaluronic acid (HA) moiety were performed and similarly 
evaluated for carrier system potential.  Incorporation of HA into the PSA-PCL 
micelle allows for potential targeting of the drug delivery system to joint tissue, 
localizing the drug’s effect to predominantly diseased tissue. 
Materials 
 Colominic acid sodium salt (PSA, isolated from E. coli, MW 30 kDa) was 
obtained from Nacalai USA (San Diego, CA). N-(3- Dimethylaminopropyl)-N0-
ethylcarbodiimide (EDCI), N,N0-dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide (NHS), ethylenediamine, m-chloro-peroxybenzonic acid, 
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benzyl alcohol, 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), e-caprolactone (e-CL), 
and Boc-gly-OH were purchased from Sigma-Aldrich (St. Louis, MO) and used 
as received. (Dimethylamino)pyridine-p-toluensulfonic acid (DPTS) was formed 
from hydrated p-toluenesulfonic acid and 4-(dimethylamino) pyridinium 
following a known protocol.14  Trifluoroacetic acid (TFA) (peptide synthesis 
grade), HPLC grade acetonitrile, dichloromethane, and anhydrous DMSO were 
also obtained from Sigma-Aldrich.  Hyaluronic Acid (50K MW) was obtained 
from Creative PEGWorks (Chapel Hill, NC). 
PCL-Amine Synthesis 
 As shown in Figure 1, PCL-OH was transformed into an amine-terminated 
variant in order to improve amide bond connectivity to PSA, done through a Boc-
glycine intermediate structure. 5.2 mg of DCC, 7.3 mg DPTS, and 4.4 mg Boc-
glycine-OH were dissolved in 12mL of distilled dichloromethane (CH2Cl2), 
stirring under a nitrogen atmosphere. 200 mg of PCL-OH (.05mmol) were added 
and allowed to stir for 48 hours at room temperature.  DCC activates the Boc-
glycine to be conjugated to the PCL through the terminal hydroxyl group acting 
as the nucleophile with the carbonyl group.  The PCL-Boc complex was added 
drop-wise to 300 mL of cold methanol, precipitating out the product.  After 
filtration, the product was dried at 75°C under vacuum for 24 hours.   
 The amine product was obtained by deprotection of the Boc group.  The 
PCL-Boc was re-dissolved in 12mL CH2Cl2, 12 mL TFA was added via syringe, 
and the solution was stirred under nitrogen for 2 hours.  The final product was 
obtained by rotary evaporation to remove excess CH2Cl2, followed by drying in 
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vacuum oven at 75°C for 48 hours, resulting in a slightly red transparent solid.  
The process had a yield of 79.4% and successful Boc addition and deprotection 
was confirmed by 1HNMR. 
 
Figure 1.  The synthesis outline of amine-terminated PCL   
 
PSA Ion Exchange 
 With the primary colominic acid sodium salt, the sodium ion was 
exchanged with tetrabutylammonium using ion exchange resin.  600 mg of 
Dowex 50 WXZ resin was mixed with 750 mg tetrabutylammonium bromide 
(TBAB) (2.26 mmol) in 15 mL DI water for 3 hours.  The resin particles were 
vacuum filtered and washed with DI water to remove excess TBAB.  The resin 
was added to 10 mL of 2% aqueous PSA (weight/weight) (200mg PSA, 0.65 
mmol sialic acid monomer).  This mixture was stirred overnight at room 
temperature.  After stirring, the mixture was filtered to remove the resin and the 
flow-through was lyophilized to obtain the final product, as seen in Figure 2.   
This image cannot currently be displayed.
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Figure 2.  Synthesis outline for PSA t-butylammonium salt 
 
PSA-PCL Conjugation 
 Amine terminated PCL was conjugated to the PSA chain to complete the 
micelle complex as shown in Figure 3.  Initially, 109 mg of PSA (.1965 mmol 
monomer) was dissolved in 10 mL anhydrous DMSO with 4.5 mg DCC and 6.4 
mg DPTS (.0197 mmol, .1 eq each) and stirred under nitrogen for 1 hour to 
activate the carbonyl groups for addition.  159 mg PCL (.0197 mmol, .1 eq) was 
dissolved in 10 mL CH2Cl2 simultaneously and stirred, for a 10% PCL 
conjugation.  After 1 hour, the PCL solution was added to the PSA via canula and 
stirred for 48 hours.   
 The reaction was stopped, filtering the solution through ~2cm 
diatomaceous earth to remove urea side product. The off-white opaque flow 
through was transferred to a 6-8,000 dalton molecular weight cut-off dialysis 
membrane, and dialyzed against 50 mM NaCl for 24 hours, then dialyzed against 
DI water for another 24 hours.  The product was next lyophilized, yielding a white 
solid.  Upon 1HNMR analysis, excess PCL was found in the product, which was 
subsequently dissolved in excess DI water (25 mL) and filtered through a medium 
This image cannot currently be displayed.
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filter, removing an off-white solid.  The cloudy flow-through was re-lyophilized, 
yielding a purer PSA-PCL product.  
 
Figure 3.  PSA-PCL synthesis scheme 
   
HA Addition 
 Following PSA-PCL synthesis, similar carbonyl addition chemistry was 
used to attach the HA ligand through a dihydrazide linker as in Figure 4.  125 mg 
of PSA-PCL (.321 mmol) was dissolved in 20 mL DI water, and 10 mg EDC 
(.0643 mmol, .2eq), 7.4 mg NHS (.0643 mmol, .2 eq), and 5.6 mg ADH (.0321 
mmol, .1 eq) were added and allowed to stir, targeting a 10% ADH conjugation.  
EDC/ NHS chemistry was used as an alternative to the DCC/DPTS used in PSA-
PCL conjugation, in order to capitalize on the amine nucleophile from the ADH 
linker, as opposed to the hydroxyl of the PCL-OH.   1M HCl was added drop-
wise to adjust pH to 4.7, and the solution was allowed to stir at room temperature 
for 2 hours.  The pH was normalized to 7.0 with NaOH.  To utilize the other end 
of the amide linker, 10 mg EDC (.0643 mmol, .2eq), 7.4 mg NHS (.0643 mmol, .2 
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eq), and 96.3 mg HA (.0321 mmol, .1 eq) were stirred in 10 mL DI water for 30 
minutes at room temperature to activate the HA carbonyl groups.  The solution 
was added to the PSA-PCL-ADH solutions and stirred overnight, resulting in a 
cloudy white solution, but with no precipitates.  The solution was added to a 6-
8,000 dalton molecular weight cut-off dialysis membrane to aid in product 
isolation and solvent exchange, and then dialyzed against DI water for 24 hours 
before lyophilization to obtain the final product.   
  
 
 
 
 
 
                                    PSA-PCL-HA 
Figure 4.  Synthesis scheme for ADH & HA addition to make PSA-PCL-HA 
 
 Additionally, PSA-PCL-HA was synthesized with only 5% HA 
conjugation in order to evaluate the effects of altered HA content on micelle 
properties.  Smaller individual particles were hypothesized to yield smaller 
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micelles and facilitate micelle assembly.  This was achieved by scaling the ADH 
and HA reagents in the previously described reaction by .5 (along with EDC and 
NHS components).   
 An alternative novel approach was also explored in regards to HA addition 
into the PSA-PCL micelle system.  Separate amphipathic copolymers, PSA-PCL 
and PCL-HA, were synthesized and then combined to create a random aggregate 
micelle with HA containing regions, PSA-PCL[PCL-HA].  The significantly 
reduced polymer size and steric mobility was hypothesized to lower size and 
CMC values.  As seen in Figure 4., a similar reaction to PSA-PCL conjugation 
was performed to link PCL and HA.   37.9 mg 50k MW HA (.1mmol, 1eq) was 
stirred in ~8mL DMSO under nitrogen for 1 hour with 2.1 mg DCC (.01mmol, 
.1eq) and 3 mg DPTS (.01mmol, .1eq) to activate the HA carbonyl groups.  80 mg 
PCL-NH2(.01mmol, .1eq) was simultaneously dissolved in equal volume CH2Cl2.  
The mixtures were combined to form a hazy solution, but with no distinguishable 
particles, and stirred under nitrogen for 48 hours.  The reaction solution was 
filtered through diatomaceous earth over a fine fretted filter, and rinsed 
thoroughly with 1:1 DMSO and CH2Cl2, yielding a relatively clear flow through.  
The flow through was rotary evaporated to reduce the solvent volume and then 
dialyzed against DI water for 24 hours to trade solvents, exchanging bath after 2, 
4, and 8 hours.  As the dialysis progressed, an opaque white solution formed, but 
with no precipitates.  The product was lyophilized to obtain a white clumpy 
powder.  H1NMR analysis revealed excess unbound PCL-NH2.  Following 
suspension of the product in DI water, repeated washing in a separatory funnel 
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with CH2Cl2 followed by lyophilization of the aqueous layer purified the final 
product.  A yield of 38% was achieved after the subsequent purification steps. 
 
Figure 5.  Synthesis scheme for PCL & HA conjugation to yield PCL-HA.  This 
could be used in a controlled combination with PSA-PCL. 
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Chapter 3 
PSA-PCL-HA Polymers: Characterization Methods & Results 
 
 
 
 
 
 Following synthesis of PSA-PCL-HA, characterization methods allow 
elucidation of pharmaceutical properties.   
Critical Micelle Concentration (CMC) 
 In order to assess the compound’s ability to spontaneously assemble into 
micelle particles, the CMC was found to quantify the minimum concentration at 
which micelles form.  A 1.24 ×10-2 M pyrene stock was made in acetone, and 8.1 
μL (1nmol) was added to 9 glass vials.  The vials were placed on a heating plate 
at 65°C for 15 minutes to evaporate the solvent.  Simultaneously, a 2x dilution 
series of PSA-PCL and PSA-PCL-HA was made from 1mg/mL to 3.9μg/mL, 
initially dissolving 2 mg of product in 2 mL DI water.  The solutions were 
transferred to the pyrene-containing vials and sonicated for 30 minutes, then 
stirred at 65°C for 4 hours and cooled overnight in the dark to equilibrate the 
solutions.  A fluorescence excitation scan was performed with solutions in a 
quartz cuvette, with an excitation scan from 300-380 nm and emission wavelength 
of 390 nm.  The hydrophobic and hydrophilic peaks were seen at around 320 and 
335 nm.  The log of the concentration was plotted against the ratio of the peaks at 
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337 and 334 nm (shifting in hydrophobic peak), and the CMC was determined to 
be the intersection of the tangent of the inflection point with the horizontal 
tangent of the low concentration points.  PSA-PCL had a CMC of ~40 μg/mL, 
comparable to previously seen values.14,16  PSA-PCL-HA had a CMC of 205 
μg/mL, roughly 5 times the value without the HA ligand.  Upon lowering the HA 
conjugation to 5%, a CMC of 169 μg/mL was seen. 
            
 
Figure 5.  The CMC results for PSA-PCL (left) and PSA-PCL-10%HA (right), 
showing tangent lines for CMC calculations. X-axis is log(polymer 
concentration), y-axis is the 
 
Size and Zeta Potential 
 Size and zeta potential of PSA–PCL and PSA-PCL-HA micelles were 
obtained as previously done14 with a Zetasizer Nano ZS (Malvern Instruments). 
Aqueous samples were prepared by dissolving samples in DI water. For dynamic 
light scattering, the temperature for measurement was 25°C, and the angle of 
y = 0.4655x + 1.2145R² = 1
y = 0.2292x2 + 1.0156x + 1.5445R² = 0.9921
y = 0.5511
-3 -2 -1 0
y = 0.123x + 1.0546R² = 0.8293
-2.5 -1.5 -0.5 0.5
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scattered light was 173°. Micelle sizes are reported as the mean of the sizes 
derived from the number distributions, while size distributions are reported as the 
mean of the polydispersity indices (PDIs).  PSA-PCL had a size of 35-50nm, low 
PDI near .08, and zeta potential of -33.  This correlated to previously achieved 
values for PSA-PCL.16  PSA-PCL-HA showed a highly distributed size around 
100 nm, PDI of .4, and zeta potential of -20mV.  Upon reduction of HA to 5% 
PSA conjugation, similar results were seen, with the observed size, PDI, and zeta 
potential around 100nm, .4, and -22mV, respectively.   The large size 
distributions of PSA-PCL-HA required filtering through a .5μm filter to remove 
larger particles in the solution outside the range of detection of the instrument 
used. 
 PCL-HA was hypothesized to create an aggregate micelle with smaller 
individual assembled polymers.  After initial synthesis, a 5 wt% PCL-HA in PSA-
PCL solution was made for CMC analysis, yielding the PSA-PCL[PCL-HA] 
aggregate micelle solution.  A 1mg/mL solution of the mixture was subjected to 
size and zeta potential testing after filtering through a 5μm cell culture filter.  A 
double-peaked size distribution was seen with peaks near 85nm and 505nm. The 
sample had a zeta potential of -33mV.   
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Figure 6.  Size distribution for filtered solution of 5wt% PCL-HA and PSA-PCL 
micelles, showing bimodal peak distribution. 
 
FILTERED Peak 1 % Peak 2 % PDI Z-Average 
Run 1 498.1 0.052 75.49 0.948 0.371 537.5 
Run 2 505.2 0.077 83.37 0.923 0.451 524.7 
Run 3 512.8 0.115 96.37 0.885 0.428 531.5 
Average 505.4 0.081 85.08 0.919 0.417 531.2 
Table 1.  The corresponding peak parameters, characterizing the PSA-PCL[PCL-
HA] peaks.  Note the 5-10% peak integral for the 500nm micelles. 
Chapter 4 
PSA-PCL-HA Discussion and Continuing Approach 
 
 
 
 
 
 The synthesis of PSA-PCL, as well as successful conjugation of HA to the 
PSA-PCL backbone, was verified by H1NMR.  PSA-PCL-HA synthesis 
demonstrated the ability to attach HA to an amphipathic micelle molecule in a 
controllable fashion through a symmetrical linking group.  The subsequent 
characterization revealed that the HA moiety has an affect on both micelle 
assembly and physical properties.  Compared to PSA-PCL, having a size of 35-
50nm, HA containing micelles increased in size over two fold to near 100nm.  A 
much wider range of sizes were observed as well, with a dispersed peak 
containing a small quantity of micelles over 1μm.  The larger PSA-PCL-HA 
molecule was predicted to result in an increased micelle size due to the increase in 
polymer size, however the extent of the change in size was not anticipated.  Even 
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with a decrease to 50% initial HA conjugation (.05 eq to PSA), significantly 
larger particles were seen over a broad range.  Similarly, CMC values increased 
over 5 fold with the addition of HA to the PSA-PCL copolymer.  The random 
addition of PCL and HA to the PSA chain may sterically interfere with the 
polarity separation during micelle formation, leading to less favorable micelle size 
and polymer assembly.  Although HA incorporation unfavorably affected micelle 
size and CMC, the zeta potential was  
 Increases in size and CMC with HA incorporation pose problematic 
characteristics for drug delivery.  When administered in vivo, micelles must be an 
adequate size within the vasculature so as to avoid renal clearance and 
reticuloendothelial system recognition.  Additionally, a low CMC is required to 
maintain micelle stability post-administration, where a stock concentration is 
effectively diluted to the in vivo aqueous volume.  The novel approach to 
construct an aggregate copolymer micelle was explored in order to possibly 
facilitate micelle formation and reduce individual polymer and micelle size while 
maintaining controllable incorporation of HA.   
 PCL-HA synthesis was successfully achieved by amide bond formation 
between PCL and the activated carbonyl group of the glucaronic acid saccharide 
in the HA monomer.  A controlled ratio of PCL-HA and PSA-PCL could be 
achieved through the mixture of known aqueous concentrations.  After making a 
5wt% PCL-HA in PSA-PCL solution, CMC testing revealed inconclusive results 
with no definitive pattern in pyrene spectra shifting.  Upon size and zeta potential 
analysis, a bimodal size distribution was seen.  The two peaks were near 80 and 
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500nm, suggesting somewhat similar micelle composition to PSA-PCL with an 
additional mechanism resulting in larger micelles. The lower PDI with two 
separate peaks than with PSA-PCL-HA alone suggested adequately formed 
micelles, further supported by an acceptable zeta potential of -33mV.  However, 
micelle formation may not have occurred as predicted.  The integration of the 
peaks revealed approximately 5-10% of the particles forming the larger micelles.  
This correlated well with the 5% PCL-HA in solution.  A suggested mechanism 
involves the segregation of each copolymer (Figure 7), preferentially assembling 
as separate micelles.  The size difference between PSA-PCL (~30k MW PSA) 
and PCL-HA (50k MW HA) could account for the behavior if the steric 
interactions were unfavorable to integration. 
 
 
 
 
 
Figure 7.  The anticipated micelle structure with the aggregate polymer approach 
(left) versus the proposed actual formation (right). 
 
Continuing Approach 
 Additional characterization of HA containing PSA-based micelles will 
initially be necessary to optimize their assembly structure and synthesis.  Both the 
single and aggregate copolymer systems show promise as a drug delivery 
modality.  PSA-PCL-HA demonstrated micelle formation with slightly higher size 
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and CMC, while PSA-PCL[PCL-HA] has potential for more ideal properties, yet 
initially showed erratic micelle behavior.  To address PSA-PCL[PCL-HA] 
aggregation, the compatibility of the copolymers to form a joint micelle with 
equal dispersion could be further investigated by altering the relative PSA and HA 
polymer sizes.  The described possible mechanism of size separation could be 
evaluated by copolymer synthesis with varying PSA and HA polymer sizes in 
PSA-PCL and PCL-HA, respectively.  Similar size, zeta potential, and CMC 
characterization could be compared to previously synthesized systems as 
described here, indicating optimal drug delivery performance.    
 Following the development of an HA-containing drug delivery system, 
drug loading and elution assays will reveal the performance and viability of the 
system after drug encapsulation.  The ability to form a stable micelle with proper 
qualities would suggest similar outcomes with an encapsulated drug, however 
previous studies have revealed a trend of increased micelle size.14,17,18  In vitro 
behavior can be evaluated barring successful drug loading characteristics.  This 
includes cytotoxicity, cellular uptake, and ultimately protein expression levels 
being targeted by the drug. 
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